TRGT » Topics » If the combination of TC-1734 (AZD3480) administered together with other drugs that are commonly prescribed for schizophrenia is not considered to be safe, the commercial potential of TC-1734 (AZD3480) would be adversely affected.

This excerpt taken from the TRGT 10-Q filed Nov 13, 2006.

If the combination of TC-1734 (AZD3480) administered together with other drugs that are commonly prescribed for schizophrenia is not considered to be safe, the commercial potential of TC-1734 (AZD3480) would be adversely affected.

A drug that is generally safe when taken alone may not be safe or may not be as safe when taken together with other drugs. We expect AstraZeneca to conduct a small clinical trial of TC-1734 (AZD3480) administered together with multiple commonly prescribed treatments for schizophrenia in healthy volunteers to evaluate the interaction of the drugs and the combined effects on metabolism and safety. If the interaction of TC-1734 (AZD3480) and any or all of the commonly prescribed

 

37


Table of Contents

treatments for schizophrenia adversely affects the metabolism of TC-1734 (AZD3480) such that TC-1734 (AZD3480) and any of those treatments are determined to be unsafe together, it could limit the commercial potential of TC-1734 (AZD3480) as a treatment for cognitive deficits in schizophrenia. Moreover, AstraZeneca could decide not to advance TC-1734 (AZD3480) as a treatment for cognitive deficits in schizophrenia, which would limit the overall commercial potential of TC-1734 (AZD3480). Furthermore, if the interaction of TC-1734 (AZD3480) with any of these commonly prescribed treatments adversely affects the metabolism of TC-1734 (AZD3480), AstraZeneca could decide not to conduct any Phase II clinical trials of TC-1734 (AZD3480) and terminate its agreement with us. If AstraZeneca terminates our agreement, it would delay our development of TC-1734 (AZD3480).

This excerpt taken from the TRGT 10-Q filed Aug 11, 2006.

If the combination of TC-1734 (AZD3480) administered together with other drugs that are commonly prescribed for schizophrenia is not considered to be safe, the commercial potential of TC-1734 (AZD3480) would be adversely affected.

A drug that is generally safe when taken alone may not be safe or may not be as safe when taken together with other drugs. We expect AstraZeneca to conduct a small clinical trial of TC-1734 (AZD3480) administered together with multiple commonly prescribed treatments for schizophrenia in healthy volunteers to evaluate the interaction of the drugs and the combined effects on metabolism and safety. If the interaction of TC-1734 (AZD3480) and any or all of the commonly prescribed treatments for schizophrenia adversely affects the metabolism of TC-1734 (AZD3480) such that TC-1734 (AZD3480) and any of those treatments are determined to be unsafe together, it could limit the commercial potential of TC-1734 (AZD3480) as a treatment for cognitive deficits in schizophrenia. Moreover, AstraZeneca could decide not to advance TC-1734 (AZD3480) as a treatment for cognitive deficits in schizophrenia, which would limit the overall commercial potential of TC-1734 (AZD3480). Furthermore, if the interaction of TC-1734 (AZD3480) with any of these commonly prescribed treatments adversely affects the metabolism of TC-1734 (AZD3480), AstraZeneca could decide not to conduct any Phase II clinical trials of TC-1734 (AZD3480) and terminate its agreement with us. If AstraZeneca terminates our agreement, it would delay our development of TC-1734 (AZD3480).

EXCERPTS ON THIS PAGE:

10-Q
Nov 13, 2006
10-Q
Aug 11, 2006
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki